Tempus AI, Inc. - TEM
About Gravity Analytica
Recent News
- 03.30.2026 - Biomarker strategy for an inhibitor in bladder cancer
- 03.27.2026 - Impact of M2-like macrophage infiltration on RCC immunotherapy outcomes
- 03.27.2026 - Developing a gene expression signature for first-line treatment in metastatic CRC
- 03.27.2026 - Characterizing the real-world mTNBC landscape to inform strategy
- 03.27.2026 - Prognostic impact of TP53 and PPP2R1A mutations in endometrial cancer
- 03.27.2026 - High WRN expression and immunotherapy outcomes in MSI-H/dMMR colorectal cancer
- 03.27.2026 - Stratifying HR+ HER2- breast cancer through ER signaling and G2/M molecular signatures
- 03.27.2026 - IL33 expression as a predictor of immunotherapy response in NSCLC
- 03.27.2026 - Characterizing CLDN18.2 and HER2 expression in gastroesophageal cancer
- 03.27.2026 - Mutational profiles and treatment resistance in metastatic TNBC